Shareholders to Vote on Highly Dilutive Equity Plan and Quorum-Assisting Preferred Stock Amidst Going Concern
COSM is trading near its 52-week low of $0.246 (5.9% above the low) on elevated volume (2.4× avg).
Summary
Cosmos Health Inc. is seeking shareholder approval for a new equity plan with substantial dilution potential and a unique preferred stock class to ensure meeting quorums, against a backdrop of financial distress and a significant disconnect between executive pay and company performance.
Key Events · Corporate Governance and Compliance · COSM
-
Highly Dilutive Equity Incentive Plan Proposed
Shareholders will vote on a new 2026 Omnibus Equity Incentive Plan reserving 10,000,000 shares for awards, representing a potential 16.68% dilution based on current outstanding shares. This follows previous large equity grants and comes amidst the company's 'going concern' warning.
-
Quorum-Assisting Preferred Stock Introduced
A proposal seeks approval for Series B Preferred Stock with 100,000,000 votes, exclusively for establishing a quorum at shareholder meetings. This mechanism aims to mitigate operational risk from low retail investor engagement but does not grant voting power on substantive matters.
-
Significant Executive Compensation Disconnect
The filing reveals a substantial gap between executive compensation and company performance. CEO Grigorios Siokas received $3.55 million in total compensation in 2025, while the company reported a net loss of $19.1 million and negative total shareholder return.
-
Compliance Failures Noted
Several insiders, including the CEO and CFO, failed to timely file Section 16(a) reports for incentive shares granted in December 2025, indicating internal control weaknesses.
Analysis · COSM · Trade & Services
Shareholders are asked to approve a new equity incentive plan that could add 10 million shares, representing a potential 16.68% dilution to existing shareholders. This comes as the company faces a 'going concern' warning and has recently filed for significant share resale. Additionally, a proposal for Series B Preferred Stock, granting 100 million votes solely for quorum purposes, highlights challenges in shareholder engagement and governance. The filing also reveals a significant disconnect between executive compensation and the company's negative financial performance, with the CEO receiving $3.55 million in 2025 while the company reported a $19.1 million net loss and negative shareholder returns. Multiple insiders also failed to timely file Section 16(a) reports, indicating compliance weaknesses.
At the time of this filing, COSM was trading at $0.26 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $15.6M. The 52-week trading range was $0.25 to $1.32. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.